Non-Immediate, Severe Hypersensitivity Reaction to Iopamidol with Cross Reactivity to Different Radiocontrast Agents  by Makris, Michael et al.
Allergology International Vol 62, No1, 2013 www.jsaweb.jp 145
Dear Editor
Non-Immediate, Severe Hypersensitivity
Reaction to Iopamidol with Cross
Reactivity to Different
Radiocontrast Agents
Iodinated contrast media (ICMs) are among the most
commonly used injectable drugs. It is estimated that
more than 75 million administrations are made per
year worldwide. ICMs are tri-iodinated benzene de-
rivatives. According to the chemical structure, osmo-
larity, iodine content and ionization in solution they
are classified as : ihigh-osmolar ionic monomers
( amidotrizoate and ioxitralamate ) , iilow-osmolar
ionic dimmers (ioxaglate), iiilow-osmolar non-ionic
monomers ( iohexol, ioversol, iomeprol, iopentol,
iopamidol, iopramide and iobitridol ) , and iviso-
osmolar non-ionic dimmers (iodixanol).1
ICMs are considered safe with most of the re-
ported adverse reactions being mild and self-limited.
Hypersensitivity reactions to ICMs can be either im-
mediate (occurring within the 1st hour after the injec-
tion) or non-immediate (occurring from 1 hour up to
7 days after the injection). Large observational stud-
ies have shown an incidence of mild immediate ad-
verse reactions of 3.8-12.7% and 0.7-3.1% among pa-
tients receiving intravenous injections of high-
osmolar ionic and low-osmolar non-ionic ICMs re-
spectively, while severe reactions have been reported
in 0.1-0.4% and 0.02-0.04% , respectively. 2,3 On the
other hand, the frequency of non-immediate adverse
reactions ranged from 0.5 to 23%, reflecting difficul-
ties in confirming causal relationship with ICM injec-
tion. 4 Most ICM-induced non-immediate reactions
are manifested by various types of skin eruptions.
Well-documented systemic reactions are rarely re-
ported.
We present the case of a 64-year old caucasian
male who was submitted to a contrast computerized
tomography examination with intravenous iopamidol
( IOPAMIROⓇ 370 mg) , a low osmolar non-ionic
monomer ICM, for the investigation of a persistent
lower abdominal pain, in May 2011. Within 24 hours
following the ICM injection, the patient experienced
generalized pruritus, while in 48 hours an intensely
pruritic erythematous maculopapular rash developed,
appearing first on the neck and legs, spreading pro-
gressively and becoming generalized. At this time, a
general practitioner administered methylpredniso-
lone 250 mg iv. Nevertheless, the rash gradually dete-
riorated and 6 days after the ICM injection, the pa-
tient was referred to us with intense pruritus, general-
ized maculopapular eruption (Fig. 1A), fever (38℃)
and a burning sensation in his eyes. From his medi-
cal history, atopy was excluded. He was not taking
any other medication and his drug history was other-
wise unremarkable. Two years before, he had re-
ceived an unknown ICM during computerized to-
mography uneventfully. Laboratory investigation re-
vealed eosinophilia (960 elementsmm3) and ele-
vated C-reactive protein (16.2 mgdl) while coagula-
tion parameters and routine chemistry and blood cul-
tures were inconspicuous. A punch biopsy of lesional
skin revealed spongiosis, a sparse mixed lympho-
monocytic inflammatory infiltrate distributed around
the superficial dermal vessels and few fragmented
neutrophils (nuclear dust) as shown in Figure 2. The
patient was treated with methylprednisolone i.v. (1
mgkg, tapered by 50% every 2 days for 6 days) and
H1-antihistamines (cetirizine, 10 mg bid). Symptoms
subsided during the next 4 days while the eruption
resolved within 10 days.
Eight weeks after the reaction, according to the re-
cently published European multicenter study, 5 skin
prick and patch tests using undiluted ICM and intrad-
ermal tests with 100- and 10-fold dilutions of iopami-
dol and alternative ICMs ( Iobitridol-XenetixⓇ 300
mg; low osmolar non-ionic monomer and Iodixanol-
VisipaqueⓇ 300 mg; isosmolar non-ionic dimer) were
carried out. All tests performed, including skin prick
tests, were positive at the 48-hour reading demon-
strating cross reactivity between the tested ICM
preparations. Intradermal tests in 1100, 110 dilu-
tions and patch tests (duplicated) at 48-hour reading
are shown on Figure 1B, 1C, respectively. Irritant re-
actions were excluded by using 10 adult controls (5
without and 5 with uneventful previous use of ICMs
injection) that underwent the same skin testing with-
out positive reactions in any of them.
In non-immediate reactions to ICMs specific T cells
seem to be involved.4 This is supported by positive
patch and intradermal tests at late readings time
points.5 In a recent study of 22 patients with delayed
hypersensitivity reactions to iodixanol, maculopapu-
lar rash in 90%, the delayed skin test results with io-
dixanol were positive in 11 (50.0%) patients while only
2 of 22 (9%) had both delayed positive IDT and patch
test results.6 Furthermore, these reactions cannot be
prevented by premedication, as it has been repeat-
edly reported.4,6
In the literature, there are several reports of non-
immediate reactions to ICM.7 Most of these refer to
maculopapular eruptions. Cross-reactivity among the
ICM, even across the four groups, is not uncommon
in non-immediate reactions.8 The present case is in-
teresting in that a severe non immediate systemic hy-
persensitivity reaction occurred and it was associated
with demonstration of cross reactivity between the
culprit agent ( iopamidol ) and ICMs of different
classes. In the study of Hasdenteufel et al.,6 cross re-
activity to ionic, nonionic, or both types of ICM was
detected in 7 out of 22 cases.
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Fig.　1　A. Patient’s exanthema the 6th day after ICM injection; B. the 48-hours positive in-
tadermal tests in 1 : 100 (left) and 1 : 10 (right) ICM dilutions; C. the 48-hours positive 
patch tests in undiluted ICM (duplicated).
A B C
Fig.　2　Histological picture of lesional skin.
As recently shown, particularly in patients with
broad skin test positivity to many different RCM, hy-
persensitivity to iodine seems to be a possible expla-
nation and should be investigated9 ; in our case an
oral provocation with Lugol’s solution was not carried
out due to the severity of the reaction.
Conclusively, although clinicians are often reluc-
tant to perform skin testing in ICMs, especially in
non-immediate reactions, skin and patch tests proved
to be highly specific 8,9 when performed properly. 5
Therefore, they should be performed whenever such
reactions occur. Due to the extended use of ICMs in
various diagnostic procedures that may necessitate
again their use in the future, the allergological diag-
nostic approach can be the basis for the selection of a
safe alternative agent.10
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